Lee's Pharmaceutical Holdings (SEHK:950) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

950 Aperçu des actions

950 analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	1/6
Performances passées	0/6
Santé financière	5/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 16.14% par an

Analyse des risques

Les revenus ont diminué de 3.4% par an au cours des 5 dernières années

Des éléments non récurrents importants ayant un impact sur les résultats financiers

Les marges bénéficiaires (1.6%) sont inférieures à celles de l'année dernière (4.2%)

N'a pas de capitalisation boursière significative ( HK$701M )

Lee's Pharmaceutical Holdings Limited Concurrents

Lansen Pharmaceutical Holdings

SEHK:503

HK$750.6m

Jilin Province Huinan Changlong Bio-pharmacy

SEHK:8049

HK$801.2m

Zhongzhi Pharmaceutical Holdings

SEHK:3737

HK$846.3m

JBM (Healthcare)

SEHK:2161

HK$725.0m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Lee's Pharmaceutical Holdings
Historique des cours de bourse
Prix actuel de l'action	HK$1.15
Plus haut sur 52 semaines	HK$1.75
Plus bas sur 52 semaines	HK$1.00
Bêta	0.90
1Variation sur 1 mois	1.77%
Variation sur 3 mois	-0.86%
Variation sur 1 an	-13.53%
3Variation sur 3 ans	-70.81%
Variation sur 5 ans	-67.24%
Évolution depuis l'introduction en bourse	121.15%

Nouvelles et mises à jour récentes

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07

Recent updates

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Have Insiders Sold Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Recently?

Dec 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In Lee's Pharmaceutical Holdings Limited (HKG:950)

Dec 08

Rendement pour les actionnaires

	950	HK Pharmaceuticals	HK Marché
7D	-6.5%	2.1%	1.4%
1Y	-13.5%	11.7%	4.6%

Rendement vs Industrie: 950 a sous-performé le secteur Hong Kong Pharmaceuticals qui a rapporté 13.4 % au cours de l'année écoulée.

Rendement vs marché: 950 a sous-performé le marché Hong Kong qui a rapporté 6.2 % au cours de l'année écoulée.

Volatilité des prix

Is 950's price volatile compared to industry and market?
950 volatility
950 Average Weekly Movement	5.0%
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	6.3%
10% most volatile stocks in HK Market	13.2%
10% least volatile stocks in HK Market	3.4%

Cours de l'action stable: 950 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de 950 ( 5% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1994	1,057	n/a	www.leespharm.com

Lee's Pharmaceutical Holdings Limited, une société holding d'investissement, développe, fabrique, commercialise et vend des produits pharmaceutiques principalement en République populaire de Chine. Elle se concentre sur diverses maladies, notamment les maladies cardiovasculaires, la santé féminine, la pédiatrie, les maladies rares, l'oncologie, la dermatologie et l'obstétrique. Elle exerce ses activités dans les secteurs des produits brevetés et génériques et des produits sous licence.

Lee's Pharmaceutical Holdings Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de Lee's Pharmaceutical Holdings se comparent-ils à sa capitalisation boursière ?
950 statistiques fondamentales
Capitalisation boursière	HK$677.16m
Bénéfices(TTM)	HK$16.70m
Recettes(TTM)	HK$1.05b

40.6x

Ratio P/E

0.6x

Ratio P/S

Le site 950 est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
950 compte de résultat (TTM)
Recettes	HK$1.05b
Coût des recettes	HK$501.72m
Marge brute	HK$551.31m
Autres dépenses	HK$534.61m
Les revenus	HK$16.70m

Derniers bénéfices déclarés

Dec 31, 2023

Prochaine date de publication des résultats

Aug 28, 2024

Résultat par action (EPS)	0.028
Marge brute	52.35%
Marge bénéficiaire nette	1.59%
Ratio dettes/capitaux propres	9.8%

Quelles ont été les performances à long terme de 950?

Voir les performances historiques et les comparaisons

Dividendes

1.6%

Rendement actuel des dividendes

63%

Ratio de distribution

950 Aperçu des actions

Récompenses

Analyse des risques

Lee's Pharmaceutical Holdings Limited Concurrents

SEHK:503

HK$750.6m

SEHK:8049

HK$801.2m

SEHK:3737

HK$846.3m

SEHK:2161

HK$725.0m

Historique des prix et performances

Nouvelles et mises à jour récentes

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong

Board Member recently bought HK$59k worth of stock

Board Member recently bought HK$117k worth of stock

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Recent updates

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong

Board Member recently bought HK$59k worth of stock

Board Member recently bought HK$117k worth of stock

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought HK$231k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

Board Member recently bought HK$381k worth of stock

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate